PRTG vs. FNCH, UTRS, SNGX, PALI, DRUG, SNPX, AFIB, GTBP, STSS, and PXMD
Should you be buying Portage Biotech stock or one of its competitors? The main competitors of Portage Biotech include Finch Therapeutics Group (FNCH), Minerva Surgical (UTRS), Soligenix (SNGX), Palisade Bio (PALI), Bright Minds Biosciences (DRUG), Synaptogenix (SNPX), Acutus Medical (AFIB), GT Biopharma (GTBP), Sharps Technology (STSS), and PaxMedica (PXMD). These companies are all part of the "medical" sector.
Finch Therapeutics Group (NASDAQ:FNCH) and Portage Biotech (NASDAQ:PRTG) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, valuation, risk, earnings, profitability, institutional ownership, analyst recommendations and community ranking.
Finch Therapeutics Group has a beta of 0.46, suggesting that its stock price is 54% less volatile than the S&P 500. Comparatively, Portage Biotech has a beta of 0.96, suggesting that its stock price is 4% less volatile than the S&P 500.
21.8% of Finch Therapeutics Group shares are held by institutional investors. Comparatively, 13.4% of Portage Biotech shares are held by institutional investors. 44.9% of Finch Therapeutics Group shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Portage Biotech received 3 more outperform votes than Finch Therapeutics Group when rated by MarketBeat users. Likewise, 59.09% of users gave Portage Biotech an outperform vote while only 52.63% of users gave Finch Therapeutics Group an outperform vote.
Finch Therapeutics Group has higher revenue and earnings than Portage Biotech. Finch Therapeutics Group is trading at a lower price-to-earnings ratio than Portage Biotech, indicating that it is currently the more affordable of the two stocks.
Portage Biotech has a consensus price target of $8.50, suggesting a potential upside of 3,050.48%. Given Finch Therapeutics Group's higher probable upside, analysts plainly believe Portage Biotech is more favorable than Finch Therapeutics Group.
Portage Biotech's return on equity of -136.63% beat Finch Therapeutics Group's return on equity.
In the previous week, Finch Therapeutics Group had 1 more articles in the media than Portage Biotech. MarketBeat recorded 1 mentions for Finch Therapeutics Group and 0 mentions for Portage Biotech. Portage Biotech's average media sentiment score of 0.34 beat Finch Therapeutics Group's score of 0.00 indicating that Finch Therapeutics Group is being referred to more favorably in the media.
Summary
Finch Therapeutics Group beats Portage Biotech on 8 of the 15 factors compared between the two stocks.
Get Portage Biotech News Delivered to You Automatically
Sign up to receive the latest news and ratings for PRTG and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PRTG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Portage Biotech Competitors List
Related Companies and Tools
